Evidence map›Paper›PMID 41714729›Full record

ArticleThe EMBO journal2026

TRPML1 suppresses pulmonary fibrosis by limiting collagen and elastin deposition.

Eva-Maria Weiden, Zala Serianz, Yvonne Klingl, Simone Jörs, Dawid Jaślan, Marco Keller, Sandra Prat Castro, Mane Mkhitaryan, Aicha Jeridi, Daria Briukhovetska and 20 more

Abstract read
In one paragraph

Article in The EMBO journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Eva-Maria Weiden *Walther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians-University, Munich, Germany.ORCID http://orcid.org/0000-0001-9582-4448
Zala Serianz *Walther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians-University, Munich, Germany.ORCID http://orcid.org/0009-0009-5753-3637
Yvonne Klingl *Immunology, Infection and Pandemic Research IIP, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Munich/Frankfurt, Germany.ORCID http://orcid.org/0000-0003-2779-3357
Simone Jörs *TUM School of Medicine and Health, Department of Clinical Medicine - Clinical Department for Internal Medicine II, University Medical Center, Technical University of Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-5721-2878
Dawid JaślanWalther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians-University, Munich, Germany.ORCID http://orcid.org/0000-0002-0685-7633
Marco KellerDepartment of Pharmacy, Ludwig-Maximilians-University, Munich, Germany.ORCID http://orcid.org/0000-0003-4792-3980
Sandra Prat CastroWalther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians-University, Munich, Germany.
Mane MkhitaryanWalther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians-University, Munich, Germany.ORCID http://orcid.org/0009-0008-7426-3088
Aicha JeridiComprehensive Pneumology Center, Institute of Lung Biology and Disease, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany.
Daria BriukhovetskaDivision of Clinical Pharmacology, Department of Medicine IV, University Hospital Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-2073-2335
Barbara SpixWalther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians-University, Munich, Germany.
Anna Scotto RosatoWalther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians-University, Munich, Germany.
Ahmed AgamiComprehensive Pneumology Center, Institute of Lung Biology and Disease, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany.
Herbert B SchillerComprehensive Pneumology Center, Institute of Lung Biology and Disease, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany.
Suhasini RajanWalther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians-University, Munich, Germany.
Johann SchredelsekerWalther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians-University, Munich, Germany.ORCID http://orcid.org/0000-0002-6657-0466
Giorgio FoisDepartment of Physiology, University of Ulm, Ulm, Germany.ORCID http://orcid.org/0000-0001-5414-1149
Manfred FrickDepartment of Physiology, University of Ulm, Ulm, Germany.
Sebastian KoboldDivision of Clinical Pharmacology, Department of Medicine IV, University Hospital Munich, Munich, Germany.
Margarethe KleinInstitute for Neurophysiology, Hannover Medical School, Hannover, Germany.ORCID http://orcid.org/0000-0002-3919-8427
Fabian GeislerTUM School of Medicine and Health, Department of Clinical Medicine - Clinical Department for Internal Medicine II, University Medical Center, Technical University of Munich, Munich, Germany.
Jorge Garcia-FortanetCasma Therapeutics, 201 Brookline Ave, Boston, MA, 02215, USA.ORCID http://orcid.org/0009-0006-9232-2198
Leon O MurphyCasma Therapeutics, 201 Brookline Ave, Boston, MA, 02215, USA.
Franz BracherDepartment of Pharmacy, Ludwig-Maximilians-University, Munich, Germany.ORCID http://orcid.org/0000-0003-0009-8629
Christian Wahl-SchottInstitute of Cardiovascular Physiology and Pathophysiology, Ludwig-Maximilians-University, Munich, Germany.
Thomas GudermannWalther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians-University, Munich, Germany.ORCID http://orcid.org/0000-0002-0323-7965
Alexander DietrichWalther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians-University, Munich, Germany.ORCID http://orcid.org/0000-0002-1168-8707
Martin BielDepartment of Pharmacy, Ludwig-Maximilians-University, Munich, Germany. martin.biel@cup.uni-muenchen.de.ORCID http://orcid.org/0000-0002-9974-3052
Ali Önder YildirimComprehensive Pneumology Center, Institute of Lung Biology and Disease, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany. oender.yildirim@helmholtz-muenchen.de.ORCID http://orcid.org/0000-0003-1969-480X
Christian GrimmWalther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians-University, Munich, Germany. christian.grimm@med.uni-muenchen.de.ORCID http://orcid.org/0000-0002-0177-5559

Funding

Deutsche Forschungsgemeinschaft (DFG) GR4315/6-1Deutsche Forschungsgemeinschaft (DFG) GR4315/7-1Deutsche Forschungsgemeinschaft (DFG) GRK2338 P08Deutsche Forschungsgemeinschaft (DFG) GRK2338 P09Deutsche Forschungsgemeinschaft (DFG) SFB1328 A21Deutsche Forschungsgemeinschaft (DFG) SFB/TRR152 P04Deutsche Forschungsgemeinschaft (DFG) SFB/TRR152 P046Deutsche Forschungsgemeinschaft (DFG) SFB/TRR152 P12Deutsche Forschungsgemeinschaft (DFG) SFB/TRR152 P15Deutsche Forschungsgemeinschaft (DFG) SFB/TRR152 P16EC | European Research Council (ERC) Grant 101100460EC | European Research Council (ERC) Grant 101124203EC | European Research Council (ERC) Grant 756017EC | Horizon Europe | Excellent Science | HORIZON EUROPE Marie Sklodowska-Curie Actions (MSCA) Grant 101168810EC | Horizon Europe | Excellent Science | HORIZON EUROPE Marie Sklodowska-Curie Actions (MSCA) Grant 955575
6 · The paper itself

Abstract

In pulmonary fibrosis lung tissue is thickened and scarred, and the lungs become progressively stiffer and smaller, leading to low levels of blood oxygen and shortness of breath. Lung fibrosis is not curable and life expectancy is reduced. Fibrosis is characterized by an increased accumulation of extracellular matrix (ECM) proteins such as collagen and elastin. ECM proteins are degraded predominantly by matrix metalloproteinases (MMPs). Here, we show that the lysosomal cation channel TRPML1, which causes the lysosomal storage disorder mucolipidosis type IV (MLIV) when mutated or lost, regulates the levels of MMPs in the ECM of mouse airways, modulating exocytosis of MMP2, 8, 9, 12, and 19, which mediate collagen/elastin degradation. While TRPML1 loss reduces MMP levels in lung macrophage and fibroblast supernatants, small molecule activation of TRPML1 results in increased levels. MLIV mice display a fibrosis-like lung phenotype similar to the phenotype evoked by bleomycin. We thus identify TRPML1 as a regulator of MMP release in the lung with loss of TRPML1 resulting in lung fibrosis due to excessive extracellular collagen and elastin accumulation.

Indexed as

CollagenElastinPulmonary FibrosisTransient Receptor Potential ChannelsAnimalsFibroblastsHumansLungMatrix MetalloproteinasesMiceMice, KnockoutCollagenElastinMatrix MetalloproteinasesMcoln1 protein, mouseTransient Receptor Potential ChannelsMcoln1Pulmonary FibrosisTRPMLTRPML1TRPML3

Identifiers

PMID41714729
PMCPMC13043727

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.